The results of the Phase III EMBER-3 trial of imlunestrant, a next-generation oral selective oestrogen receptor degrader (SERD) for patients with hormone receptor-positive breast cancer in ER-positive, HER2-negative advanced breast cancer (ABC), were presented at the SABCS. The study shows that patients with an ESR1 mutation in particular benefit.
Autoren
- Birke Dikken
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- Prevention of skin cancer
UV protection and skin cancer screening – Update 2025
- Case report: L. pneumophila pneumonia
Negative test results – but no alternative diagnoses
- Clinical case reports and implications for GP care
Magnesium deficiency and dilated cardiomyopathy in the peripartum context
- SID Annual Meeting: Highlights
Update on inflammatory dermatoses – a concentrated load of innovative power
- Case series
Bleeding prophylaxis for von Willebrand disease
- A critical analysis of the evidence from 113 studies
Nutrition and depression
- An emerging interface with clinical relevance
Lung cancer and neuroscience
- Acute leukemia: Disease management